Use case · Indication expansion

Find the next indication for an existing asset, with the evidence behind each option

Causaly connects an asset’s mechanism to the diseases that share it, then weighs the biology, clinical signals, unmet need and competition for each candidate indication, with every claim cited.

Why it matters

New indications are often chosen on scattered evidence

Candidate indications surface from mechanism, case reports, trials and competitor moves, usually in different places. Weighing them on the same criteria, with the counter-evidence in view, helps teams pursue the strongest options and drop weak ones early.

Start from the mechanism

Trace an asset’s target and pathways to the diseases where they play a role, using Bio Graph relationships and the literature.

Check for signals and precedent

See the clinical and preclinical findings, trials and drug programs that point to, or argue against, each candidate indication.

Weigh need and competition

Set each indication against its unmet need, patient population and the drugs already approved or in development.

What it is

What is indication expansion with Causaly?

Indication expansion, also called drug repurposing or repositioning, means finding new diseases an existing asset could treat. Causaly gathers the mechanistic, clinical and competitive evidence for each candidate indication, so your team can compare them and decide which to pursue.

For a formal, repeatable comparison against your team’s own decision criteria, see Indication Prioritization, a tailored solution configured with your experts.

648M+

scientific relationships across Bio Graph and Pipeline Graph

40M+

biomedical publications and preprints

550K

clinical trial records

159K

drugs tracked in Pipeline Graph

Indexed content as of October 2026. New literature reaches Bio Graph within about four weeks of publication.

How it works

How Causaly helps you find and assess new indications

Ask Agentic Research which diseases share an asset’s mechanism, then use library workflows to assess need, population and competition for the strongest candidates.

  • Input

    An asset and its mechanism

    Start from a drug, a target or a pathway, and add any indications you want to include or rule out.

  • Evidence

    Biology, signals and landscape

    Causaly searches Bio Graph, the literature, clinical trial records and Pipeline Graph, plus connected sources such as Open Targets, ChEMBL and openFDA.

  • Assessment

    Candidates compared on the same criteria

    Workflows such as Unmet Needs Assessment, Epidemiology Profile and Treatment Landscape Assessment add need, population and competition for each indication.

  • Output

    A cited case for each option

    Supporting and contradicting evidence sit side by side. Ask follow-up questions and export reports to Word, PDF or PowerPoint.

Key capabilities

What your team can do with Causaly

From a first question about where else an asset could work to a cited case for each option, the evidence for every step sits in one place.

Map mechanism to disease

Find diseases linked to an asset’s target and pathways through Bio Graph cause-and-effect relationships, each traced to its source.

Find clinical and preclinical signals

Surface studies, case reports and trials suggesting activity in a new indication, alongside the evidence that argues against it.

Size the patient population

The Epidemiology Profile workflow compiles incidence, prevalence and burden of a disease by geography.

Assess unmet need

The Unmet Needs Assessment workflow maps gaps in efficacy, safety and durability, and the subgroups where better options are needed.

See the competition

Pipeline Graph and the Treatment Landscape Assessment workflow show approved and pipeline drugs and the white space between them.

Check safety in a new setting

Adverse event data from openFDA, FDA labels from DailyMed and the Target Safety Profile workflow help flag liabilities for a new population.

Optional: connect internal data through the Enterprise Data Fabric or your own MCP connectors, so your team’s findings are read alongside the public evidence.

“If I didn't use Causaly, finding relevant papers would really be left up to chance. I really need Causaly to give me the starting point for my research.”
Global Regulatory Affairs, Head of EU Region · Top 20 pharma

Indication expansion: common questions

How does Causaly find candidate indications?

Agentic Research traces an asset’s target and pathways to diseases where they play a role, using Bio Graph relationships and the literature, then looks for clinical and preclinical signals and existing drug programs in each disease. Every link is cited.

Which data sources does Causaly use?

Bio Graph and Pipeline Graph (648M+ scientific relationships), more than 40 million publications and preprints and 550,000 clinical trial records, plus connected sources such as Open Targets, ChEMBL, openFDA and DailyMed.

How is this different from indication prioritization?

Indication expansion is about finding and assessing new indications for an asset. Indication Prioritization is a Causaly solution that compares a set of indications against your team’s own decision criteria, configured with your experts, so the ranking is repeatable.

Can Causaly assess unmet need and competition?

Yes. The Unmet Needs Assessment, Epidemiology Profile and Treatment Landscape Assessment workflows cover need, population and competition, and Pipeline Graph shows the drugs in development for each indication.

Can Causaly use our internal data?

Yes, as an option. Internal documents can be connected through the Enterprise Data Fabric, and your own MCP connectors can be added to Agentic Research. Causaly does not use customer data to train models.

Bring an asset your team wants to take further

We’ll explore candidate indications with you and walk through the evidence for each one.